Spelling suggestions: "subject:" alzheimer's disease""
171 |
"Estudo comparativo do desempenho em testes neuropsicológicos de pacientes com diagnóstico de doença de Alzheimer e demência vascular" / Comparative study of the performance of patients with Alzheimer´s disease and vascular dementia in neuropsychological testsMatioli, Maria Niures Pimentel dos Santos 26 October 2005 (has links)
A doença de Alzheimer (DA) e a demência vascular (DV), especialmente a sua forma subcortical, são responsáveis pela maioria dos quadros de demência em idosos, nem sempre facilmente diferenciadas do ponto de vista clínico. O objetivo do estudo foi comparar o desempenho de pacientes com DA e com DV em uma bateria breve de testes cognitivos (Mini-exame do estado mental e bateria Neuropsi para confirmar o diagnóstico de demência; CLOX 1 e 2, fluência verbal categoria animal e fonêmica, EXIT 25 e teste de memória tardia da bateria breve de rastreio cognitivo), e verificar seu valor no diagnóstico diferencial entre elas. O desempenho do grupo DV foi inferior ao DA nos testes: CLOX 2, fluência verbal animal e fonêmica. O grupo DA obteve desempenho inferior a DV no subitem evocação do teste de memória tardia. / Alzheimers disease (AD) and vascular dementia (VaD), especially its subcortical form, are responsible for the majority of dementia cases in the elderly and are not always easily differentiated from a clinical point of view. The aim of this study was to compare the performance of mild VaD and AD patients in a series of brief cognitive tests (Mini-mental State Examination and Neuropsi battery, in order to confirm the diagnosis of dementia; CLOX 1 and 2, category and letter fluency, a delayed recall test of 10 simple figures and the EXIT 25), and to evaluate the potential use of these tests for the differential diagnosis between them. The performance of the VaD group was significantly impaired, in relation to the AD group, in the tests CLOX 2, category verbal fluency and letter verbal fluency, while the AD patients performed significantly worst in the delayed recall test.
|
172 |
The effect of danshen on tau phosphorylation: a possible treatment strategy for Alzheimer's disease.January 2004 (has links)
Hung Shieh-Jung Fanny. / Thesis submitted in: August 2002. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2004. / Includes bibliographical references (leaves 97-109). / Abstracts in English and Chinese. / Acknowledgements --- p.i / Abstract --- p.ii / 摘要 --- p.iv / Content --- p.vi / List of Abbreviations --- p.xiii / List of Figure --- p.xv / List of Tables --- p.xix / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Alzheimer's Disease (AD) --- p.1 / Chapter 1.1.1 --- Clinical features --- p.2 / Chapter 1.2 --- Histopathological studies of AD --- p.2 / Chapter 1.2.1 --- Neuritic plaques --- p.2 / Chapter 1.2.2 --- Neurofibrillary tangles (NFT) --- p.4 / Chapter 1.2.3 --- Tau --- p.5 / Chapter 1.3 --- Kinases and Alzheimer's Disease --- p.7 / Chapter 1.4 --- Free radical damage --- p.8 / Chapter 1.5 --- Available treatment for AD --- p.7 / Chapter 1.6 --- A Chinese medicinal material 一 Danshen ((Salviae miltiorrhizcie) --- p.11 / Chapter 1.6.1 --- Chemical constituents --- p.11 / Chapter 1.6.1.1 --- Lipophilic Compounds of Danshen --- p.12 / Chapter 1.6.1.2 --- Water-soluble Compounds of Danshen --- p.17 / Chapter 1.6.2 --- Pharmacological usage --- p.20 / Chapter 1.6.2.1 --- Action on Coronary system --- p.20 / Chapter 1.6.2.2 --- Bacteriostatic action --- p.21 / Chapter 1.6.2.3 --- Actions on the immune system --- p.21 / Chapter 1.6.3 --- Biological activity on brain --- p.22 / Chapter 1.7 --- Objectives and scope of the project --- p.23 / Chapter Chapter 2 --- General Materials and Method --- p.24 / Chapter 2.1 --- Recombinant DNA techniques --- p.24 / Chapter 2.1.1 --- Preparation of E. coli strain DH-5a competent cells --- p.24 / Chapter 2.1.2 --- Transformation of plasmid DNA into competent cells --- p.25 / Chapter 2.1.3 --- Preparation of plasmid DNA using QIAGEN Plasmid Maxipreps kit --- p.25 / Chapter 2.1.4 --- Phenol/ choroform extraction of DNA --- p.26 / Chapter 2.1.5 --- Spectrophotometric quantitation of the amount and purity of DNA --- p.27 / Chapter 2.2 --- Drugs preparation --- p.27 / Chapter 2.2.1 --- Preparation of aqueous extracts of Traditional Chinese Medicine (TCM) --- p.27 / Chapter 2.2.2 --- Preparation of ethanol extracts of Traditional Chinese Medicine (TCM) --- p.27 / Chapter 2.3 --- "3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium (MTT) assay " --- p.28 / Chapter 2.4 --- Analysis of proteins from culture cells --- p.28 / Chapter 2.4.1 --- Extraction of total proteins from culture cells --- p.28 / Chapter 2.4.2 --- Quantitation of protein by Bradford method --- p.29 / Chapter 2.4.3 --- Protein separation by sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) --- p.29 / Chapter 2.4.4 --- Western blot analysis --- p.31 / Chapter 2.5 --- Reagents and buffers --- p.32 / Chapter 2.5.1 --- Reagents for competent cell preparation --- p.32 / Chapter 2.5.2 --- Reagents provided by QIAGEN Plasmid Maxipreps kit --- p.33 / Chapter 2.5.3 --- Reagents for SDS-PAGE --- p.34 / Chapter 2.5.4 --- Reagents and buffers for Western Blotting --- p.35 / Chapter 2.5.5 --- Cell lines --- p.36 / Chapter 2.5.6 --- Antibodies --- p.37 / Chapter 2.5.7 --- Plasmids --- p.37 / Chapter 2.5.8 --- Other Chemicals --- p.38 / Chapter Chapter 3 --- The effect of Danshen on GSK-3 induced hyperposphorylation of tau in Cos7 cells / Chapter 3.1 --- Introduction --- p.39 / Chapter 3.1.1 --- Glycogen synthase kinase-3 (GSK-3) --- p.39 / Chapter 3.1.2 --- Structure of GSK-3 --- p.39 / Chapter 3.1.3 --- The importance of GSK-3 in AD --- p.39 / Chapter 3.2 --- Materials and Methods --- p.41 / Chapter 3.2.1 --- Transfection of Gsk-3 and tau into Cos7 monkey kidney cells --- p.43 / Chapter 3.2.2 --- Extraction of total proteins from culture cells --- p.44 / Chapter 3.2.3 --- Quantitation of protein by Bradford method --- p.44 / Chapter 3.2.4 --- Protein separation by sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) --- p.44 / Chapter 3.2.5 --- Western blot analysis --- p.44 / Chapter 3.3 --- Results --- p.45 / Chapter 3.3.1 --- Toxicity test on Cos7 cells --- p.45 / Chapter 3.3.2 --- The effect of ethanol extract of Danshen on GSK-3 β induced tau phosphorylation --- p.45 / Chapter 3.3.3 --- The effect of aqueous extract of Danshen on GSK-3 β induced tau phosphorylation --- p.48 / Chapter 3.3.4 --- The effect of Protocatechualdehyde on GSK-3β induced tau phosphorylation --- p.48 / Chapter 3.3.5 --- The effect of Salvianolic acid B on GSK-3β induced tau phosphorylation --- p.49 / Chapter 3.4 --- Discussion --- p.60 / Chapter Chapter 4 --- Cdk5 induced hyperposphorylation of tau in CHO cells / Chapter 4.1 --- Introduction --- p.63 / Chapter 4.1.1 --- Cyclin dependent kinase 5 (Cdk5) --- p.63 / Chapter 4.1.2 --- Structure of Cdk5 --- p.63 / Chapter 4.1.3 --- Neurological functions of Cdk5 --- p.64 / Chapter 4.2 --- Materials and Methods --- p.66 / Chapter 4.2.1 --- Transfection of p35 and tau into CHO cells --- p.66 / Chapter 4.2.2 --- Extraction of total proteins from culture cells --- p.67 / Chapter 4.2.3 --- Quantitation of protein by Bradford method --- p.67 / Chapter 4.2.4 --- Protein separation by sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) --- p.67 / Chapter 4.2.5 --- Western blot analysis --- p.67 / Chapter 4.3 --- Results --- p.68 / Chapter 4.3.1 --- Toxicity test on CHO cells --- p.68 / Chapter 4.3.2 --- Tau transfection in Cdk5/p35 and TauON3R transiently transfected in CHO cells --- p.68 / Chapter 4.3.3 --- Effect of roscovitine treatment on the transiently tau and p35 transfection in CHO cells --- p.74 / Chapter 4.3.4 --- "Effects of aqueous active components of Danshen, PCAH and SAB on the transiently tau and p35 transfection in CHO cells " --- p.74 / Chapter 4.4 --- Discussion --- p.79 / Chapter Chapter 5 --- Antioxidant effect of Danshen and its active components on lipid peroxidation / Chapter 5.1 --- Introduction --- p.81 / Chapter 5.1.1 --- Red-blood-cell hemolysis model --- p.82 / Chapter 5.2 --- Materials and methods --- p.84 / Chapter 5.2.1 --- Red-blood-cell hemolysis model --- p.84 / Chapter 5.2.2 --- Materials --- p.85 / Chapter 5.2.2.1 --- Animals --- p.85 / Chapter 5.2.2.2 --- Chemicals --- p.85 / Chapter 5.3 --- Results --- p.86 / Chapter 5.3.1 --- Aqueous and ethanol extracts of Danshen --- p.86 / Chapter 5.3.2 --- Active components ´ؤ Protocatechualdehyde and Salvianolic acid B --- p.87 / Chapter 5.4 --- Discussion --- p.91 / Chapter Chapter 6 --- General discussion and Outlook / Chapter 6.1 --- General discussion --- p.93 / Chapter 6.2 --- Proposed study in the future --- p.95 / Chapter 6.2.1 --- In vitro kinase assay using gamma32 P ATP and substrate with or without TCM --- p.95 / Chapter 6.2.2 --- Use of neuroblastoma cells (SHSY-5Y) to study the effect of Danshen and its active components on tau phosphorylation --- p.95 / Chapter 6.2.3 --- Thiobarbituric acid-reacting substances (TBARS) assay --- p.96 / Chapter 6.2.4 --- In vitro phosphatase kinase assay --- p.96
|
173 |
Novel usage of medicinal herbs for treating Alzheimer disease.January 2004 (has links)
by Tsz-Wan Ho. / Thesis submitted in: July 2003. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2004. / Includes bibliographical references (leaves 107-122). / Abstracts in English and Chinese. / Acknowledgements --- p.i / Abstract --- p.ii / 摘要 --- p.iv / Content --- p.vi / Abbreviations --- p.x / List of Figures --- p.xi / List of tables --- p.xiv / Chapter CHAPTER 1 --- GENERAL INTRODUCTION --- p.1 / Chapter 1.1 --- Alzheimer'sDisease --- p.1 / Chapter 1.2 --- Hallmarks of AD --- p.3 / Chapter 1.2.1 --- The amyloid cascade hypothesis --- p.3 / Chapter 1.2.2 --- The tauopathy hypothesis --- p.4 / Chapter 1.3 --- The Cholinergic Hypothesis --- p.6 / Chapter 1.3.1 --- Cholinergic drug therapy --- p.7 / Chapter 1.3.2 --- Acetylcholinesterase inhibitors --- p.8 / Chapter 1.3.2.1 --- Tacrine --- p.10 / Chapter 1.3.2.2 --- Donepezil --- p.10 / Chapter 1.3.2.3 --- Rivastigimine - ENA-713 --- p.11 / Chapter 1.4 --- AChE inhibitors from plants --- p.12 / Chapter 1.4.1 --- Galanthamine --- p.12 / Chapter 1.4.2 --- Huperzine --- p.14 / Chapter 1.4.3 --- α-onocerin --- p.15 / Chapter 1.4.4 --- (+)-alpha-viniferin --- p.16 / Chapter 1.5 --- My project --- p.17 / Chapter CHAPTER 2 --- MATERIALS AND METHODS --- p.18 / Chapter 2.1 --- Preparation of CMM --- p.18 / Chapter 2.2.1 --- Selecting criteria and sources --- p.18 / Chapter 2.2.2 --- Preparation of aqueous extract --- p.18 / Chapter 2.2.3 --- Preparation of ethanol extract --- p.18 / Chapter 2.3 --- Routine maintenance of cell lines --- p.19 / Chapter 2.4 --- Toxicity test --- p.19 / Chapter 2.5 --- Ellman assay --- p.20 / Chapter 2.6 --- Ellman assay over BuChE --- p.21 / Chapter 2.7 --- Drugs --- p.21 / Chapter CHAPTER 3 --- SCREENING OF ACETYLCHOLINESTERASE INHIBITORS FROM CHINESE MEDICINAL MATERIALS --- p.23 / Chapter 3.1 --- Introduction --- p.23 / Chapter 3.2 --- Materials and Methods --- p.23 / Chapter 3.3 --- Results and discussion --- p.24 / Chapter 3.3.1 --- Preliminary screening of 45 selected TCMs for AChE inhibition --- p.24 / Chapter 3.3.2 --- Rescreening of drugs that show AChE inhibition in both aqueous and organic extracts --- p.25 / Chapter 3.4 --- Discussion --- p.28 / Chapter CHAPTER 4 --- CHARACTERIZATION OF ANTI-ACETYLCHOLINESTERASE ACTIVITY FROM SALVIA MBLTIORRHIZA BGE.(丹參) --- p.33 / Chapter 4.1 --- Introduction --- p.33 / Chapter 4.1.1 --- Clinical application of Danshen --- p.34 / Chapter 4.1.2 --- Pharmacological properties of Danshen and Salvia species --- p.34 / Chapter 4.1.2.1. --- Antiinflammatory and antibacterial responses --- p.35 / Chapter 4.1.2.2 --- Diabetes --- p.35 / Chapter 4.1.2.3 --- Alcoholism --- p.35 / Chapter 4.1.2.4 --- Apoptosis --- p.36 / Chapter 4.1.2.5 --- The effect of Salvia extracts on neuro-receptors --- p.36 / Chapter 4.1.3 --- Anti-cholinesterase activity by the Salvia species --- p.37 / Chapter 4.1.4 --- Active components from Salvia miltiorrhiza Bge --- p.38 / Chapter 4.2 --- Effects of tanshinone derivatives on AChE --- p.39 / Chapter 4.2.1 --- Materials and Methods --- p.39 / Chapter 4.2.2. --- Results --- p.39 / Chapter 4.3 --- Discussion --- p.50 / Chapter CHAPTER 5 --- EXTRACTION OF CRYPTOTANSHINONE FROM SALVIA MILTIORRHIZA --- p.54 / Chapter 5.1 --- Introduction --- p.54 / Chapter 5.1.1 --- Reverse phase high performance liquid chromatography (RP-HPLC) --- p.55 / Chapter 5.2 --- Materials and Methods --- p.56 / Chapter 5.2.1 --- Extracts of Danshen from different sources for obtaining the chemical profile --- p.55 / Chapter 5.2.2 --- Reverse phase high performance liquid chromatography (RP-HPLC) --- p.57 / Chapter 5.2.2.1 --- Analytical RP-HPLC --- p.57 / Chapter 5.2.2.2 --- Preparative RP-HPLC --- p.58 / Chapter 5.3 --- Results --- p.60 / Chapter 5.3.1 --- Identification of Peaks that contain the proposed active components --- p.60 / Chapter 5.3.2 --- Different samples of Danshen contain different amount of active components that can exert inhibitory effect on hAChE --- p.66 / Chapter 5.4 --- Discussion --- p.75 / Chapter CHAPTER 6 --- EFFECT OF CRYPTOTANSHINONE ON CALCIUM MOVEMENT in SH-SY5Y Cell --- p.80 / Chapter 6.1 --- Introduction --- p.80 / Chapter 6.2 --- Materials and Methods --- p.82 / Chapter 6.2.1 --- Reagents and drugs --- p.82 / Chapter 6.2.2 --- Calcium fluorimetry --- p.82 / Chapter 6.3 --- Results --- p.85 / Chapter 6.4 --- Discussion --- p.96 / Chapter CHAPTER 7 --- GENERAL DISCUSSION --- p.98 / Chapter 7.1 --- Structure-function relationship of crytotanshinone and dihydrotanshinone I --- p.98 / Chapter 7.2 --- Further study on cryptotanshinone and dihydrotanshinone I --- p.100 / Chapter 7.2.1 --- Modulation on nictonic receptor --- p.100 / Chapter 7.2.2 --- Behavioral study on mice --- p.101 / Chapter 7.2.3 --- Large scale production of the desired active components --- p.102 / Chapter 7.3 --- Study on other candidate herbs --- p.102 / References --- p.107
|
174 |
Developing oral curcumin-HP-ß-cyclodextrin complexes to enhance Aß removal and preserve memory in Tg2576 mice.January 2012 (has links)
背景及研究目的:據報導薑黃素(curcumin)在阿爾茨海默癥(老年癡呆癥)的動物模型中表現出有效性。這可能與其能阻抑β 澱粉樣蛋白的聚集有關,而β 澱粉樣蛋白正是老年癡呆癥中達成共識的神經毒性物質。然而,薑黃素的水溶性很差,這一弱點直接限制其在作為口服藥物的生物利用度。羥丙基-β-環糊精是一種由七個單糖分子鍵合成的環狀分子,該環具有親水性的外部和疏水性的內部,這一特點使得疏水性藥物可以裝入環糊精分子內部從而提高該藥物的親水性,進而提高藥物的口服吸收率。 / 方法:包合物在50 攝氏度下,由摩爾比為1:2 的薑黃素和羥丙基-β-環糊精經過6 小時的攪拌而形成。其后对包合物的物化性質與相同摩爾比的薑黃素與羥丙基-β-環糊精的混合物的物化特性进行了对比以证实包合物的形成,诸如水溶性,掃描電鏡下的形態以及傅利葉紅外圖譜特性。接著用經包合物和普通薑黃素粉末喂食的SD 大鼠做藥代動力學研究,取出大鼠血樣然之後用高效液相色譜-質譜聯用法對薑黃素進行定量,計算出達峰時間(T{U+2098}{U+2090}{U+2093} ), 峰濃度(C{U+2098}{U+2090}{U+2093} )以及 0 到4 小時藥時曲綫下面積 (AUC₀→₄{U+2095} )從而比較包合物較普通薑黃素是否有優越之處。之後,用Tg2576 轉基因小鼠做短期研究,此种小鼠能過度表達β 澱粉樣蛋白,是一種被廣泛應用于老年癡呆癥相關科研的動物模型,經過連續7 日的喂食之後,對小鼠的β 樣澱粉蛋白進行觀察。進一步,將用能同時過度表達β 樣澱粉蛋白與神經纖維結(NTFs)的Tau/APP 轉基因小鼠做長達兩月的藥效學實驗,在實驗始末配以关联恐惧调件反应测试(CFC)和八臂迷宮(Radial Arm Maze)來對實驗小鼠的記憶失進行定量分析。處死小鼠之後,對β 樣澱粉蛋白與神經纖維結(NTFs)進行定量分析從而確定包合物在藥效學上的優勢。 / 結果:在包合的過程中,大部份的薑黃素被整合到包合物之中。通過傅利葉紅外圖譜和掃描電鏡照片都可以觀察到包合物與混合物的顯著不同。在藥代動力學研究中,普通薑黃素粉末的達峰時間為22 分鐘左右,而包合物是40 分鐘,同時,經過包合,峰濃度也提高了3 倍左右,藥時曲綫下面積提高了2 倍以上。在用Tg2576 進行的為期一周的短期實驗中,觀察不到包合物和普通薑黃素在β 樣澱粉蛋白清除方面有明顯差別,然後通過體內染色卻可以看到經包合物喂食的小鼠腦切片中可以觀察到更多的來自薑黃素的螢光信號。在2 個月的長期實驗中,就关联恐惧调件反应测试和八臂迷宮實驗的結果來看,可以觀察到包合物有更好延遲TAPP 小鼠記憶失過程的趨勢但無顯著性,除此之外,對處死后的小鼠腦部進行分析,其β 澱粉樣蛋白與神經纖維節的含量分析結果也和行為測試具有一致性。 / 結論:用羥丙基-β-環糊精對薑黃素進行包合確實可以通過增加薑黃素的水溶性從而提高其生物利用度,讓更多的薑黃素通過血腦屏障進入大腦進而與β 澱粉樣蛋白進行結合。然後短期實驗無法表明包合物具有β 澱粉樣蛋白清除效應。而長期實驗中行為實驗和處死後大腦分析顯示出較普通薑黃素而言包合物具有有限的優點,如果要證明這一優點確實存在,可能需要更長時間的喂食與另外劑量。 / Background: Curcumin is reported to be an effective treatment in animal models of Alzheimer’s disease (AD), possibly by inhibiting aggregation of amyloid-β peptides, which can be neurotoxic.However, curcumin is poorly soluble in water, limiting its oral bioavailability. Hydroxypropyl-β-cyclodextrin (HP-β-CD), a cyclic oligosaccharide made of seven sugar molecules bound togetherin a ring has a hydrophobic exterior and a hydrophobic interior, within which curcumin can reside, thus increasing the aqueous solubility of curcumin. This study aims to solve the problem of poor water-solubility of curcumin using HP-β-CD. / Method: The inclusion complexes were formed by stirring a suspension of curcumin and HP-β-CD at a molar ratio of 1:2 at 50°C for 6 hr. Physicochemical properties, including watersolubility,morphology under scanning electron microscopy (SEM) and the Fourier Transform Infrared (FTIR) spectrum, varied between the inclusion complex and a physical mixture of the two compounds. The inclusion complex and curcumin powder were fed to Sprague Dawley rats for pharmacokinetic studies, from which blood samples were analyzed using LC/MS/MS, and relevant parameters such as T{U+2098}{U+2090}{U+2093}, C{U+2098}{U+2090}{U+2093} and AUC₀→₄{U+2095} were calculated to study the effect of HP-β-CD on the bioavailability of curcumin. To evaluate the pharmacodynamic effects, Tg2576 mice, which over express amyloid-β, were treated for 7 consecutive days with curcumin powder or inclusion complexes. Further, to examine effects of long-term treatment, Tau/APP mice, a commonly used AD model producing both amyloid-β and mutant tau proteins, were treated for 2 months. Behavior tests were conducted at the beginning and end of the long-term treatment to quantify the memory loss of the mice, and post mortem analyses, including quantification of amyloid-β plaques and neurofibrillary tangles, were performed after sacrificing the mice. / Result: The majority of curcumin was integrated into complexes. FTIR profiles and SEM photographs of complexes displayed significant differences from the physical mixture. In the pharmacokinetic study, the concentration of curcumin in the control group peaked at around 22.5 min, while that of inclusion complexes peaked around 40 min. The maximum concentration of curcumin trebled and the area under the curve from 0 to 4 hours more than doubled. For shortterm treatment in Tg2576 mice, paraffin sections stained with Thioflavin T, a dye detecting amyloid-β plaques, showed no obvious difference between mice treated with curcumin powder or complexes; however brain sections from complex-treated mice had more fluorescence signal from curcumin than did mice treated with curcumin powder. For long-term treatment, in terms of the results of contextual fear conditioning and radial arm maze, there was a trend toward inclusion complexes delaying the memory loss of Tau/APP mice more effectively than curcumin powder. Compared to curcumin powder, complexes tended to reduce the number of plaques and neurofibrillary tangles. / Conclusion: Complexation with HP-β-CD can significantly enhance curcumin bioavailability by increasing its water-solubility, allowing more curcumin to penetrate the blood brain barrier to bind to amyloid-β plaques. However, short-term treatment showed no advantage of inclusion complexes in clearing amyloid-β plaques. The results of behavior tests and post-mortem studies from the 2-month long-term treatment indicated limited superiority of inclusion complexes over curcumin powder. A longer feeding period or altered dosage or both might be necessary to enhance the effect of curcumin inclusion complexes. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Liu, Hao. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2012. / Includes bibliographical references (leaves 104-117). / Abstracts also in Chinese. / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Overview of Alzheimer’s disease --- p.1 / Chapter 1.1.1 --- The pathological mechanisms of Alzheimer’s disease --- p.2 / Chapter 1.1.2 --- Anti-Alzheimer’s disease drugs --- p.3 / Chapter 1.2 --- Curcumin as a potential anti-AD agent --- p.5 / Chapter 1.2.1 --- Actions of curcumin on Aβ --- p.6 / Chapter 1.2.2 --- Anti-inflammatory and anti-oxidant activities of curcumin in AD --- p.8 / Chapter 1.2.3 --- Activities of curcumin to combat metal toxicity --- p.9 / Chapter 1.3 --- The physicochemical properties of curcumin and limitations of curcumin in clinical usage --- p.12 / Chapter 1.4 --- Cyclodextrin in pharmaceutical usage --- p.18 / Chapter 1.5 --- Aims of the study --- p.23 / Chapter Chapter 2 --- Preparation and characterization of curcumin-HP-β-CD complexes --- p.24 / Chapter 2.1 --- Introduction --- p.24 / Chapter 2.2 --- Phase solubility study --- p.24 / Chapter 2.1.2 --- Preparation of solid complexes --- p.28 / Chapter 2.1.3 --- Characterization of solid complexes --- p.29 / Chapter 2.1.4 --- Previous work on the curcumin HP-β-CD inclusion complex --- p.31 / Chapter 2.2 --- Methodology --- p.33 / Chapter 2.2.1 --- Phase solubility test --- p.33 / Chapter 2.2.2 --- Preparation of curcumin-CD complexes --- p.33 / Chapter 2.2.3 --- Recovery --- p.35 / Chapter 2.2.4 --- Differential solubility --- p.36 / Chapter 2.2.5 --- SEM Studies --- p.37 / Chapter 2.2.6 --- Infrared --- p.37 / Chapter 2.3 --- Results and discussion --- p.38 / Chapter 2.3.1 --- Phase solubility analysis --- p.38 / Chapter 2.3.2 --- Recovery test --- p.40 / Chapter 2.3.3 --- Differential solubility --- p.42 / Chapter 2.3.4 --- SEM study --- p.44 / Chapter 2.3.5 --- Infrared study --- p.45 / Chapter Chapter 3 --- Staining of amyloid plaques in Tg2576 mice after oral administration of curcumin-HP-β-cyclodextrin inclusion complex --- p.47 / Chapter 3.1 --- Introduction --- p.47 / Chapter 3.2 --- In vitro staining of amyloid plaques by thioflavin T and curcumin --- p.49 / Chapter 3.2.1 --- Thioflavin T and curcumin specifically binding to amyloid plaques --- p.49 / Chapter 3.2.2 --- Chemicals --- p.51 / Chapter 3.2.3 --- Method --- p.51 / Chapter 3.3 --- In vivo staining of amyloid plaques after oral administration of curcumin-HP-β-CD inclusion complex --- p.53 / Chapter 3.3.1 --- Animal treatment --- p.53 / Chapter 3.3.2 --- Method --- p.54 / Chapter 3.4 --- Results and discussion --- p.56 / Chapter 3.4.1 --- In vitro staining of amyloid plaques by thioflavin T and curcumin --- p.56 / Chapter 3.4.2 --- In vivo staining of amyloid plaques by curcumin --- p.57 / Chapter 3.4.3 --- Plaque removal effects after short-term feeding --- p.58 / Chapter Chapter 4 --- Pharmacokinetic study of curcumin in Sprague-Dawley (SD) rats after oral administration of curcumin-HP-β-cyclodextrin inclusion complex --- p.61 / Chapter 4.1 --- Introduction --- p.61 / Chapter 4.1.1 --- Previous pharmacokinetic study of curcumin-HP-β-CD inclusion complex --- p.61 / Chapter 4.1.2 --- Previously established LC/MS/MS methods for quantification of curcumin in SD rat plasma sample --- p.62 / Chapter 4.2 --- Development and validation of LC/MS/MS assay --- p.63 / Chapter 4.2.1 --- Chemicals --- p.63 / Chapter 4.2.2 --- Instrumentation and chromatographic conditions --- p.63 / Chapter 4.2.3 --- Preparation of standard solutions --- p.63 / Chapter 4.2.5 --- Validation of the assay method --- p.64 / Chapter 4.3 --- Pharmacokinetic profile of curcumin in SD rats --- p.65 / Chapter 4.3.1 --- Animals --- p.65 / Chapter 4.3.2 --- Animal treatment and blood sampling --- p.65 / Chapter 4.3.3 --- Plasma sample analysis --- p.65 / Chapter 4.3.4 --- Data analysis --- p.66 / Chapter 4.4 --- Result and discussion --- p.67 / Chapter 4.4.1 --- Mass spectrum --- p.67 / Chapter 4.4.2 --- Chromatography and specificity --- p.69 / Chapter 4.4.3 --- Linearity and sensitivity --- p.71 / Chapter 4.4.4 --- Method validation---Precision and accuracy --- p.71 / Chapter 4.4.5 --- Method validation---Liquid-liquid extraction recovery --- p.72 / Chapter 4.4.6 --- Pharmacokinetics parameters --- p.73 / Chapter Chapter 5 --- Long-term effects of curcumin-HP-β-CD inclusion complex on Alzheimer’s disease model mice --- p.79 / Chapter 5.1 --- Introduction --- p.79 / Chapter 5.1.1 --- Tau/APP trangenic mouse --- p.79 / Chapter 5.1.2 --- Memory --- p.80 / Chapter 5.1.3 --- The role of the hippocampus in memory --- p.81 / Chapter 5.1.4 --- Memory task contextual fear conditioning (CFC) --- p.82 / Chapter 5.1.5 --- Memory task radial arm maze (RAM) --- p.83 / Chapter 5.2 --- Methods --- p.85 / Chapter 5.2.1 --- Animal treatment --- p.85 / Chapter 5.2.2 --- Contextual fear conditioning test --- p.85 / Chapter 5.2.3 --- Radial arm maze test --- p.87 / Chapter 5.2.4 --- Post-mortem analysis amyloid plaque removal effects of the curcumin-HP-β-CD inclusion complex --- p.88 / Chapter 5.2.5 --- Post-mortem analysis neurofibrillary tangle removal effects of the curcumin-HP-β-CD inclusion complex --- p.90 / Chapter 5.3 --- Results and discussion --- p.92 / Chapter 5.3.1 --- Mortality of the mice --- p.92 / Chapter 5.3.2 --- Contextual fear conditioning test --- p.93 / Chapter 5.3.3 --- Radial arm maze (RAM) test --- p.95 / Chapter 5.3.4 --- Post-mortem analysis amyloid plaque removal effects of the curcumin-HP-β-CD inclusion complex --- p.97 / Chapter 5.3.5 --- Post-mortem analysis neurofibrillary tangle removal effects of the curcumin-HP-β-CD inclusion complex --- p.99 / Chapter Chapter 6 --- Conclusions and future perspective --- p.100 / Chapter 6.1 --- Conclusions --- p.101 / Chapter 6.2 --- Future perspective --- p.103 / References --- p.104
|
175 |
Ressonância magnética quantitativa das alterações estruturais do corpo caloso na doença de Alzheimer e no comprometimento cognitivo leve / Quantitative MRI of strutural changes of the corpus callosum in Alzheimer\'s disease and mild cognitive impairmentSantos, Breno William Corrêa dos 12 June 2017 (has links)
Objetivo: Avaliar a atrofia do corpo caloso (CC) em pacientes com doença de Alzheimer (DA) e comprometimento cognitivo leve (CCL) e quantificar quais regiões dessa estrutura são mais acometidas nessa doença como uso de técnicas quantitativas de ressonância magnética. Metodologia: O estudo contou com a participação de 75 indivíduos sendo 22 controles normais (CN), 30 com CCL e 23 com DA. O volume total do corpo caloso e suas 3 diferentes sub regiões foram delimitadas em cortes sagitais de imagem de ressonância magnética. Os volumes obtidos foram corrigidos para a variação de volume intracraniano. As mascaras foram co-registradas a mapas de relaxometria e transferência de magnetização para analise quantitativa. Resultados: Encontramos atrofia e redução dos valores de relaxometria e transferência de magnetização nos pacientes do grupo DA. As tres sub regiões do corpo caloso apresentaram redução de volume na doença sendo que a atrofia foi maior nas regiões anteriores. Não encontramos diferença significativa nos parâmetros estudados entre CCL e CN. Conclusões: Embora o corpo caloso esteja envolvido no processo de desconexão cortical presente na doença de Alzheimer seu envolvimento não é precoce. / Objective: To evaluate the atrophy of the corpus callosum (CC) in patients with Alzheimer disease (AD) and mild cognitive impairment (CCL) and quantify which regions of this structure are most affected in this disease as using quantitative MRI techniques. Methodology: The study counted on the participation of 75 individuals being 22 normal controls (CN), 30 with CCL and 23 with AI). The total volume of the corpus callosum and its v 3 different sub regions were delimited in sagittal sections of magnetic resonance imaging. The volumes obtained were corrected for intracranial volume variation. The masks were recorded with maps of relaxometry and transfer of magnetization for quantitative analysis. Results: We found atrophy and reduced values of relaxometry and magnetization transfer in patients in the AD group. The three sub regions of the corpus callosum showed volume reduction in the disease, with atrophy being greater in the anterior region. We found no significant difference in the parameters studied between CCL and CN fit .Conclusions: Although the corpus callosum is involved in the process of cortical detachment present in Alzheimer\'s disease, its involvement is late.
|
176 |
Síntese de potencial inibidor de acetilcolinesterase para tratamento da Doença de Alzheimer / Synthesis of potencial acetylcholinesterase inhibitor to Alzheimer disease treatmentChierrito, Talita Perez Cantuaria 09 March 2016 (has links)
A doença de Alzheimer (DA) é a forma mais comum de demência, representando cerca de 80% dos casos. A DA é caracterizada por um processo de declínio progressivo e irreversível das funções cognitivas e da memória, que se estende para a desorganização do comportamento. Atualmente, 46,8 milhões de pessoas em todo o mundo foram diagnosticadas com demência. Embora vários fatores tenham sido implicados na DA, sua etiologia ainda não é completamente conhecida. Do ponto de vista neuropatológico, é observado no cérebro de indivíduos com DA atrofia cortical difusa, presença de grande número de placas senis, emaranhados neurofibrilares, processo inflamatório e perda neuronal. A progressão dos sintomas está associada a mudanças estruturais nas sinapses colinérgicas em certas regiões do cérebro, que consequentemente, apresentam neurotransmissão colinérgica reduzida. Os vários eventos patológicos interligados contribuem para o avanço da doença e direcionam diversas pesquisas na busca por tratamentos multialvos com base no processo multifatorial de DA. Assim o presente trabalho descreve a síntese de derivados híbridos dual binding site de donepezila-tacrina (fármacos inibidores de acetilcolinesterase), com potencial para agir em dois alvos terapêuticos pela (i) inibição da acetilcolinesterase em ambos os sítios ativo e periférico, como demonstrado pelos estudos de modelagem molecular, e (ii) na agregação do peptídeo A? neurotóxico induzido pela acetilcolinesterase, na tentativa de interromper a progressão da doença. A estratégia sintética envolveu a condensação da 5,6-dimetóxiindanona com a unidade 4-piperidinil carbaldeído, a qual forneceu o intermediário 5,6- dimetóxindan-1-ona-4-piperidinil-metileno-1-[(4-cloroquinolin-2-il)metil], seguido de redução da dupla ligação, gerada na reação de condensação anterior, e substituição do átomo de cloro-quinolina por amino para obtenção do produto final, ou manutenção da função olefina, seguido de substituição do átomo de cloro-quinolina por azido ou amino, gerando cinco híbridos estruturalmente correlacionados. Os híbridos foram testados em ensaio de inibição de acetilcolinesterase e butirilcolinesterase pelo método de Ellman, e o híbrido insaturado, contendo a função amino-quinolina foi o mais ativo da série com IC50 na faixa de nanomolar (0,014 ?M). Futuramente, os intermediários da reação e produto final serão submetidos ao ensaio de inibição da agregação do peptídeo A? neurotóxico pelo método da tioflavina T. Neste trabalho, também são descritos os testes de predição in vitro para permeação pela barreira hematoencefálica, bem como sua absorção intestinal, pelo método PAMPA. / Alzheimer\'s disease (AD) is the most commom form of dementia in almost 80% of the cases. AD is a process that causes a progressive and irreversible decline of cognitive functions, memory and includes disorganized behavior. Currently, 46.8 million people live with dementia around the world. Although several factors have been implicated in AD, its etiology is not fully understood. In the point of neuropathologic view, diffuse cortical atrophy, presence of senile plaques, neurofibrillary tangles, inflammatory process and neuronal loss are observed in the brain of the patients with AD. The progression of the disease symptoms is associated with structural changes in cholinergic synapses in certain brain regions and consequent impairment of cholinergic neurotransmission. The various interconnected pathological events contribute for the progression of the disease and drive several studies in the search for multitarget treatments based on the multifactorial process of AD. Therefore, this work describes the synthesis of dual binding site tacrine-donepezil hybrids, with the potential to act in two therapeutics targets by: (i) inhibition of the acetylcholinesterase in both peripheral and active sites, as demonstrated in molecular modeling studies, and (ii) the peptide A? neurotoxic aggregation induced by acetylcholinesterase, in an attempt to stop the progression of the disease. The synthetic strategy was based on the condensation between 5,6- dimethoxy-indanone and the 4-piperidinyl carbaldehyde core, which afforded the 5,6- dimethoxy-indanone-4-piperidinyl-methylene-1-[(4-chloroquinolin-2-yl)methyl] intermediate, followed by the reduction of the olefinic bond, formed in the previous condensation, and substitution of the chloro-quinoline atom by amine group to give the final product, or keeping the olefin function, followed by replacement of the chloro-quinoline atom by azide or amine to produce five structural related hybrids. The hybrids were tested in acetylcholinesterase and butyrylcholinesterase inhibition assays using Ellman method, and the unsaturated hybrid containing the amino-quinoline function was the most active of the series with IC50 in a nanomolar range (0,014 ?M). The ability of the hybrids to inhibit protein A? neurotoxic aggregation will be assessed by thioflavin T method. In addition, the blood brain and intestinal barrier permeation by PAMPA methodology were also predicted.
|
177 |
Habilidades linguísticas de pacientes com demência vascular: estudo comparativo com a doença de Alzheimer / Linguistic abilities of vascular dementia patients: comparative study with Alzheimer diseaseMaria Isabel d'Avila Freitas 02 September 2010 (has links)
INTRODUÇÃO: Os quadros demenciais comprometem gradualmente todos os domínios cognitivos e comportamentais. Deterioração progressiva nas funções de linguagem também é observada, e pode ser uma medida importante no diagnóstico precoce de demência. É escasso o conhecimento sobre o padrão de linguagem na Demência Vascular (DV). Os poucos estudos existentes têm analisado aspectos lingüísticos isolados e produzido resultados conflitantes. A Bateria Arizona para Desordens da Comunicação em Demência (ABCD) foi desenvolvida para identificar e avaliar alterações de comunicação funcional associadas à demência, relacionando-as com habilidades de memória episódica e construção visoespacial. A inexistência de estudos utilizando a ABCD em pacientes com DV e, a necessidade de ampliar a experiência brasileira quanto ao uso desta bateria em pacientes com Doença de Alzheimer, foram os aspectos que motivaram a realização deste estudo. OBJETIVOS: Descrever as habilidades lingüísticas de pacientes com DV em fase leve e compará-las às habilidades linguísticas de pacientes com DA e idosos cognitivamente normais. MÉTODOS: Foram avaliados 23 pacientes com DV leve - GDV (médias de idade: 71,7 (6,9) e escolaridade: 9,1(5)), 20 pacientes com DA leve - GDA (médias de idade: 77,3 (3,9) e escolaridade: 6,7(4,3)) e 31 sujeitos controles - GC (médias de idade: 72,7 (6,9) e escolaridade: 9,0(4,4)) utilizando-se a ABCD e outros testes para avaliação de funções cognitivas de suporte da linguagem. RESULTADOS: Houve diferenças estatisticamente significativas entre o GDV e o GC em todas as medidas da ABCD, com exceção do subteste de Questões Comparativas do construto de Compreensão Linguística. A acurácia da ABCD foi superior a 80%, em todos os construtos e no escore total da ABCD, para discriminação entre GDV e GC. A comparação entre o GDV e o GDA mostrou diferenças estatisticamente significativas nas medidas de dois construtos da ABCD. Memória Episódica, Expressão Linguística (subteste de Nomeação por Confrontação). Conclusão: As habilidades linguísticas dos pacientes com DV leve mostraram-se prejudicadas em todos os subtestes de Expressão e Compreensão linguística da ABCD, com exceção do subteste de Questões Comparativas. Diferenças linguísticas entre os pacientes com DV leve e os pacientes com DA leve foram observadas somente no subteste de Nomeação por Confrontação da ABCD / INTRODUCTION: Dementia gradually affects all cognitive and behavioral domains. A progressive deterioration in language is also observed, and may be used as an important measure in the differential diagnosis. Little is known about the language pattern in Vascular Dementia (VaD). The few existing studies have addressed specific aspects of language and produced conflicting results. The Arizona Battery of Communication Disorders in Dementia (ABCD) was designed to identify and evaluate functional communication disorders and other abilities as episodic memory and visuospatial construction in dementia. The lack of studies using the ABCD in patients with VaD, and the need to expand the Brazilian experience in the use of this battery in patients with Alzheimer\'s Disease (AD), were the aspects that motivated this study. OBJECTIVES: To describe the linguistic abilities in mild VaD patients compared to AD patients and cognitively normal elderly. METHODS: We evaluated 23 mild VaD patients - VaDG (mean age: 71,7(6,9) and schooling: 9,1(5)), 20 mild AD patients - ADG (mean age: 77,3(3,9) and schooling: 6,7(4,3)) and 31 controls - CG (mean age: 72,7(6,9) and schooling: 9,0(4,4)) using the ABCD and tests to evaluate cognitive functions supporting language. RESULTS: There were statistically differences significant between VaDG and CG in all ABCD measures, except for the subtest Comparative Question from Linguistic Comprehension Construct. The accuracy of the ABCD was above 80% to discriminate VaDG and CG in all constructs. Comparison between VaDG and ADG showed statistically differences significant in two constructs of ABCD: in the Episodic Memory Construct, and in the Linguistic Expression Construct (Confrontation Naming subtest). CONCLUSIONS: Linguistic abilities of mild VaD patients were impaired in all measures of the Linguistic Expression and Linguistic Comprehension Constructs, except for the Comparative Questions subtest. Linguistic differences between mild VaD patients and mild AD patients were observed only in the Confrontation Naming subtest of ABCD
|
178 |
Funcionalidade global, da deglutição e da comunicação de idosos com comprometimento cognitivo avançado / Global functionality, swallowing and communication of elderly people with advanced cognitive impairmentDaniela Tonellotto dos Santos 28 November 2018 (has links)
INTRODUÇÃO: A demência ou comprometimento cognitivo avançado é um problema frequente e cada vez mais prevalente na população idosa. A maioria dos pacientes com demência desenvolve disfagia especialmente na fase avançada da doença e tem alto risco de morte por pneumonia aspirativa. Inúmeras são as discussões a respeito da funcionalidade dos idosos com quadros demenciais; todavia, a deglutição não faz parte das escalas de funcionalidade. Além disso, a avaliação da comunicação, segue critérios equivocados, como \"quantidade de palavras emitidas por dia\". OBJETIVOS: Traçar o perfil das dificuldades de deglutição e comunicação em pacientes com comprometimento cognitivo avançado, identificar indicadores de disfagia e distúrbios da comunicação que se associem com a classificação da funcionalidade global da escala FAST e propor a inclusão de parâmetros de disfagia e funcionalidade da comunicação na escala FAST. MÉTODOS: Foram coletados dados de 107 pacientes no banco de dados do Ambulatório de Comprometimento Cognitivo Avançado (ACCA) do Serviço de Geriatria do HCFMUSP. Foram realizadas análises descritivas dos perfis de funcionalidade e correlações entre funcionalidade global, da deglutição e da comunicação dos sujeitos. RESULTADOS: 67% da amostra era do sexo feminino, com idade média de 83 anos, destros, com 4 anos de escolaridade média. Quanto ao diagnóstico, 34% da amostra foi diagnóticada com DA, 32% com demência mista (DA e DV), 21% com DV e 13% com demências menos frequentes. Em relação ao estadiamento da demência, a maioria dos sujeitos foi classificada com CDR 3 e MEEM-g 9, que corresponde a demência grave. Em média, os pacientes apresentaram cinco ou mais comorbidades associadas à demência, além de sintomas neuropsiquiátricos e neuropsicológicos. Quanto à avaliação fonoaudiológica estrutural dos órgãos fonoarticulatórios, 100% apresentou alteração nos mecanismos de contenção oral e 77% apresentou alteração de proteção das vias aéreas. Em relação a funcionalidade da deglutição, 92% da amostra pode receber dieta por via oral de forma segura, desde que observadas restrições e adaptações na dieta, além de estratégias compensatórias. Quanto à funcionalidade da comunicação, 38% não utilizaram linguagem funcional; 48% apresentaram expressão oral fragmentada com necessidade de o ouvinte/cuidador assumir a responsabilidade pela comunicação; em 14% a responsabilidade da comunicação foi compartilhada com o ouvinte. CONCLUSÃO: Foram traçadas as características do perfil, das alterações de deglutição e de comunicação dos sujeitos com comprometimento cognitivo avançado. Todavia, ainda que os perfis de deglutição e comunicação declinem conforme a funcionalidade global, na população estudada, não foi possível identificar associação entre o nível da FAST e a gravidade da disfagia ou da comunicação. O estudo contribuiu com dados sobre a funcionalidade da deglutição e da comunicação dos sujeitos com comprometimento cognitivo avançado, desconsiderados pelas tradicionais escalas de funcionalidade / INTRODUCTION: Dementia with advanced cognitive impairment is a frequent and increasingly prevalent problem in the elderly population. Most patients with dementia develop dysphagia especially at an advanced stage of the disease and are at high risk of death from aspiration pneumonia. There are many discussions about the functionality of elderly people with dementia; however, swallowing is not part of the functionality scales. Furthermore, the evaluation of communication follows misguided criteria as quantities of words per day. OBJECTIVES: To outline the difficulties of swallowing and communication in patients with advanced cognitive impairment and to identify indicators of dysphagia and communication disorders associated with the classification of the global functionality of the FAST scale and propose the inclusion of dysphagia parameters and communication functionality in the FAST scale. METHODS: Data from 107 patients were collected from the Advanced Cognitive Compromising Ambulatory (ACCA) database of the Geriatric Service of the HCFMUSP from January to December 2016. Descriptive analyzes of functional profiles and correlations between global functionality of swallowing and the communication of the subjects. RESULTS: 67% of the sample was female, with a mean age of 83 years, right-handed, with 4 years of average schooling. Regarding the diagnosis, 34% was diagnosed with AD, 32% with mixed dementia (AD and DV), 21% with DV and 13% with less frequent dementias. Regarding staging of dementia, the majority of subjects were classified as CDR 3 and MMSE-g 9, which corresponds to severe dementia. On average, patients had five or more comorbidities associated with dementia, as well as neuropsychiatric and neuropsychological symptoms. Regarding the structural speech-language evaluation of the speech-language organs, 100% of the sample presented alterations in oral containment mechanisms and 77% presented alterations in airway protection. Regarding swallowing functionality, 92% of the sample can receive oral diet safely, provided dietary restrictions and adaptations are observed, as well as compensatory strategies.Regarding communication functionality, 38% did not use functional language; 48% have fragmented oral expression and the listener / caretaker assumes responsibility for communication; 14% the responsibility for communication was balanced with the listener. CONCLUSION: Characteristics of the subjects\' profile, the swallowing and communication changes of the subjects with advanced cognitive impairment were drawn. However, although the swallowing and communication profiles declined according to the global functionality, in this population it was not possible to identify an association between the global functional level of FAST and the severity of dysphagia and communication. The study contributed data on the functionality of swallowing and communication of subjects with advanced cognitive impairment, neglected by traditional scales of functionality
|
179 |
Protection of okadaic acid-induced tau hyperphosphorylation by bioflavonoids in neuroblastoma cells.January 2008 (has links)
Pan, Tak Yin. / Thesis submitted in: November 2007. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2008. / Includes bibliographical references. / Abstracts in English and Chinese. / Acknowledgements --- p.i / Abstract (English) --- p.ii / Abstract (Chinese) --- p.iv / Content --- p.v / Abbreviations --- p.x / List of Figures --- p.xi / List of Tables --- p.xii / Chapter Chapter 1: --- Introduction --- p.1 / Chapter 1.1 --- Alzheimer's Disease --- p.1 / Chapter 1.1.1 --- Cholinergic hypothesis --- p.2 / Chapter 1.1.2 --- p-amyloid hypothesis --- p.2 / Chapter 1.1.3 --- Taupathy hypothesis --- p.3 / Chapter 1.1.4 --- Current therapies --- p.4 / Chapter 1.2 --- Proteins Involved in Alzhemer's Disease --- p.5 / Chapter 1.2.1 --- Acetylcholinesterase (AChE) --- p.5 / Chapter 1.2.2 --- p-amyloid --- p.6 / Chapter 1.2.3 --- Paired helical filaments (PHF) --- p.7 / Chapter 1.2.4 --- Protein kinases --- p.8 / Chapter 1.2.4.1 --- Glycogen synthase kinase-3 (GSK-3) --- p.9 / Chapter 1.2.4.2 --- Cyclin-dependent kinase-5 (CDK-5) --- p.9 / Chapter 1.2.5 --- Protein phosphatase (PP) --- p.10 / Chapter 1.2.5.1 --- Protein phosphatase 1 (PP-1) --- p.11 / Chapter 1.2.5.2 --- Protein phosphatise 2A (PP-2A) --- p.12 / Chapter 1.2.5.3 --- Protein phosphatise 2B (PP-2B) --- p.13 / Chapter 1.2.6 --- Apoptotic and Anti-apoptotic proteins --- p.14 / Chapter 1.2.6.1 --- Caspase-3 --- p.15 / Chapter 1.2.6.2 --- Bcl-2 --- p.15 / Chapter 1.3 --- Flavonoids --- p.16 / Chapter 1.3.1 --- Biosynthesis of flavonoids --- p.17 / Chapter 1.3.2 --- Biological functions of flavonoids in plants --- p.18 / Chapter 1.3.3 --- Beneficial effects of flavonoids on human health --- p.19 / Chapter Chapter 2: --- Materials and Methods --- p.20 / Chapter 2.1 --- Differentiation of SHSY-5Y cells --- p.20 / Chapter 2.1.1 --- SHSY-5Y cell culture --- p.20 / Chapter 2.1.2 --- Counting cells --- p.20 / Chapter 2.1.3 --- Retinoic acid differentiation --- p.21 / Chapter 2.2 --- Western blot analysis --- p.21 / Chapter 2.2.1 --- Extraction of proteins from mammalian cells --- p.21 / Chapter 2.2.2 --- Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) --- p.22 / Chapter 2.2.3 --- Semi-dry protein transfer to nitrocellulose membrane --- p.23 / Chapter 2.2.4. --- Membrane blocking and immunostaining --- p.24 / Chapter 2.3 --- MTT assay --- p.25 / Chapter 2.4 --- Hoechst 33342 Nuclei staining --- p.25 / Chapter 2.5 --- Cell cycle analysis --- p.25 / Chapter 2.5.1 --- Ethanol fixation --- p.25 / Chapter 2.5.2 --- Propidium iodide staining --- p.26 / Chapter 2.6 --- Annexin V-FITC & Propidium iodide staining --- p.26 / Chapter 2.7 --- DNA fragmentation analysis --- p.26 / Chapter 2.7.1 --- Phenol/Chloroform extraction of DNA --- p.26 / Chapter 2.7.2 --- Ethanol precipitation of DNA --- p.27 / Chapter 2.7.3 --- Agarose gel electrophoresis of DNA --- p.27 / Chapter 2.8 --- Proteomic analysis --- p.28 / Chapter 2.8.1 --- First dimension: isoelectric focusing --- p.28 / Chapter 2.8.2 --- Second dimension: SDS PAGE --- p.29 / Chapter 2.8.3 --- Gel staining --- p.30 / Chapter 2.8.3.1 --- Silver staining --- p.30 / Chapter 2.8.3.2 --- SYBRO Ruby staining --- p.31 / Chapter 2.8.4 --- Gel scanning and image analysis --- p.31 / Chapter 2.8.5 --- ln-gel digestion --- p.32 / Chapter 2.8.6 --- Zip Tip for desalting the digested sample --- p.33 / Chapter 2.8.7 --- Protein identification with mass spectrometry and database search --- p.33 / Chapter Chapter 3: --- Characterization of Okadaic acid-induced tail hyperphosphorylation in SHSY-5Y cells --- p.35 / Chapter 3.1 --- Introduction --- p.35 / Chapter 3.2 --- Objectives --- p.37 / Chapter 3.3 --- Results --- p.38 / Chapter 3.3.1 --- Differentiation of SH-SY5Y cell --- p.38 / Chapter 3.3.2 --- Changes of protein expression after okadaic acid treatment --- p.40 / Chapter 3.3.3 --- Neurite Retraction Induced by okadaic acid --- p.42 / Chapter 3.3.4 --- Okadaic acid-induced Cell Death measured by MTT assay --- p.44 / Chapter 3.3.5 --- Hoechst 33342 Nuclei Staining --- p.44 / Chapter 3.3.6 --- Cell cycle analysis by propidium iodide staining --- p.47 / Chapter 3.3.7 --- Early Apoptotic cells detection by Annexin V/PI staini --- p.49 / Chapter 3.3.8 --- DNA fragmentation --- p.51 / Chapter 3.4 --- Discussion --- p.53 / Chapter Chapter 4: --- Flavonoids screening for protecting neuronal death by preventing tau hyperphosphorylation --- p.57 / Chapter 4.1 --- Introduction --- p.57 / Chapter 4.2 --- Objectives --- p.58 / Chapter 4.3 --- Tested flavonoids --- p.59 / Chapter 4.4 --- Results --- p.60 / Chapter 4.4.1 --- Toxicity of flavonoids --- p.60 / Chapter 4.4.2 --- Effects of flavonoid pre-treatment on OA-induced neu retractions and cell death --- p.62 / Chapter 4.4.3 --- Western blot analysis --- p.65 / Chapter 4.4.4 --- The effect of different concentrations of hesperidin or OA treatment --- p.70 / Chapter 4.4.5 --- Proteomic analysis --- p.74 / Chapter 4.5 --- Discussion --- p.78 / Chapter Chapter 5: --- General Discussion --- p.82 / References
|
180 |
Study of the possible pharmacological mechanisms of curcumin in the treatment of Alzheimer's disease. / CUHK electronic theses & dissertations collectionJanuary 2011 (has links)
Cheung, Kwok Kuen. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 226-263). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.
|
Page generated in 0.0532 seconds